FDA tightening GLP‑1 compounding

The Food and Drug Administration is no longer treating compounded weight-loss shots like a gray market it can ignore. On March 3, 2026, the agency said it sent 30 warning letters to telehealth companies over false and misleading claims about compounded glucagon-like peptide-1 drugs, the class that includes semaglutide and tirzepatide. (fda.gov) Those drugs became huge because the brand names were hard to find and expensive. Semaglutide is sold by Novo Nordisk as Wegovy and Ozempic, and tirzepatide is sold by Eli Lilly as Zepbound and Mounjaro. (fda.gov) Compounding is the pharmacy version of custom mixing. A pharmacist can make a special version of a drug for a patient who needs a different dose or ingredient, but the Food and Drug Administration says compounded drugs are not approved the way brand-name or generic drugs are. (fda.gov) That distinction mattered less when shelves were empty. The Food and Drug Administration formally declared the tirzepatide injection shortage resolved on December 19, 2024, and the semaglutide injection shortage resolved on February 21, 2025. (fda.gov 1) (fda.gov 2) Once a shortage ends, the legal room for making copycat compounded versions gets much tighter. The Food and Drug Administration’s 2025 guidance said it did not intend to keep giving compounders broad enforcement discretion tied to shortage status after those deadlines passed. (fda.gov) The agency’s newer letters show where it is aiming first: marketing. In its March 2026 announcement, the Food and Drug Administration said companies were implying compounded drugs were the same as approved products and hiding who actually made the drugs by using the telehealth company’s own brand name on labels and ads. (fda.gov) One February 20, 2026 warning letter to MEDVi spelled that out in plain terms. The Food and Drug Administration said claims like “Same active ingredient as Wegovy and Ozempic” and “Same active ingredient as Mounjaro and Zepbound” were false or misleading for compounded semaglutide and tirzepatide. (fda.gov) The Food and Drug Administration is also talking about the supply chain behind those copies. In a January 2026 safety page, the agency said it was moving to restrict active pharmaceutical ingredients for non-approved compounded glucagon-like peptide-1 drugs that were being mass-marketed as similar alternatives to approved medicines. (fda.gov) Novo Nordisk pushed from the private side at the same time. Its United States news archive says the company took legal action against Hims & Hers on February 9, 2026, then announced on March 9, 2026 that Hims & Hers would shift its United States weight-loss business toward approved glucagon-like peptide-1 medicines and stop advertising compounded glucagon-like peptide-1 offerings on its platform. (novonordisk-us.com) (sec.gov) Hims & Hers said the remaining compounded semaglutide offering would be limited to a smaller group of patients whose clinical needs cannot be met by commercially available approved drugs. In the same March 9 filing, the company said existing patients could be transitioned to approved medicines when providers decide that is appropriate. (sec.gov) So the fast change here is not one ban or one lawsuit. It is the combination of shortages ending, the Food and Drug Administration moving from warnings about safety to warnings about advertising and sourcing, and big telehealth platforms starting to rewrite their business models around approved drugs instead of mass-marketed compounded ones. (fda.gov 1) (fda.gov 2) (sec.gov)